WINDLAS Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹233 Cr
verified against source
Revenue YoY
20%
reported change
EBITDA
₹32 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Windlas Biotech delivered its 12th consecutive quarter of record revenue with Q3 FY26 revenue of Rs 233 crore (up 20% YoY), driven by strong performance across all three verticals. CDMO grew 23% YoY in Q3, exports surged 36% YoY, while trade generics/institutional moderated to 7% YoY due to competitive intensity and institutional order timing. EBITDA margin expanded 40bps YoY to 13.6%, reflecting operating leverage despite incremental investments. Management highlighted that Plan 6 mechanical completion remains on track for FY26-end, adding Rs 1,000 crore capacity, with injectable capacity providing additional upside. The company refrained from quantitative guidance but emphasized focus on disciplined execution, customer diversification, and capability building. Key risks include Trade Generics growth deceleration, injectable capacity underutilization versus expectations, and reliance on India-focused revenues (95%+ domestic). Schedule M regulatory enforcement is driving industry consolidation, positioning quality-focused manufacturers like Windlas favorably. The balance sheet remains cash-generative with improving working capital.
Colored figures show movement against the previous available record.
Guidance to track
- Upon Plan 6 completion and full operationalization, total revenue capacity (excluding injectables) will reach Rs 1,000 crore, with injectables adding another Rs 100 crore on top.
- Plan 6 mechanical completion expected by end of FY26, with quality systems validation and customer audits to follow. Net net, H1 FY27 expected for full commercialization with partial contributions possible earlier through intermediate phases.
- As injectable capacity utilization improves, management will either pursue an acquisition opportunity or begin building new dosage form capacity. No specific timeline or investment quantum disclosed.
Risks flagged
- Q3 Trade Generics growth slowed to 7% YoY versus 18% for 9M FY26 and historical quarters of up to 74%. Management attributed this to competitive intensity from new entrants, institutional order lumpiness, and execution factors. Peers with 2.5x the base are growing faster.
- Management admitted injectable capacity utilization has been lower than expectations but declined to disclose specific numbers citing competitive sensitivity. No clear timeline provided to reach 70-80% utilization target.
- An analyst directly asked for 9-month net cash generation which management deflected, stating balance sheet is only limited reviewed and they want to refrain from sharing. This limits visibility into working capital efficiency and leverage.
- Over 95% of sales are domestic India. Any policy changes (NLEM pricing, PLI scheme changes), regulatory shifts, or industry volume growth data gaps (government program purchases not captured by IQVIA/Awaz) could impact revenue visibility.
Key quotes
- We have delivered 12 consecutive quarters of highest ever revenue. We want to surprise you pleasantly – that is the intent and that is the effort.
- Schedule M compliance is not just about capital access to capital. It is about knowhow, talent, and systems. This is where having multinational clients has benefited Windlas because these clients have been working with us – we get almost 70 to 80 audits a year.
- In exports, results are binary or time-bound. We might be at 70% and then we get to know this is not working out, and there are others which we don't expect and they happen earlier than expected.
Research modules